Emerging in the arena of obesity therapy, retatrutide presents a different method. Unlike many current medications, retatrutide functions as a dual agonist, at once engaging both glucagon-like peptide-1 (GLP-1) and glucose-responsive insulinotropic hormone (GIP) receptors. The concurrent engagement fosters multiple helpful effects, including improv